Arterys Oncology DL
Overview
Arterys Oncology DL is an FDA-cleared, AI-powered medical imaging software designed to enhance diagnostic efficiency and accuracy for oncologists. It leverages deep learning to automate the segmentation and tracking of lung nodules and liver lesions in CT and MRI scans, providing accurate and editable results comparable to manual segmentations by experienced clinicians.
Operating on the Arterys Medical Imaging Cloud (MICA) platform, the solution integrates seamlessly into existing PACS or EHR workflows, making it accessible from validated devices via the cloud. Arterys aims to improve physician experience, diagnostic accuracy, treatment planning, and patient outcomes by reducing tedious manual tasks and providing quantitative, intelligent insights.
The platform supports 2D and 3D visualization, semi-automatic volumetric segmentation, co-registration, longitudinal tracking, and data reporting based on Lung-RADS and LI-RADS guidelines. Arterys’ cloud-native architecture reduces IT overhead and allows healthcare facilities of any size, from major hospitals to small clinics, to access cutting-edge AI capabilities.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-powered analysis
- Cloud-based platform
- Automated segmentation of lung nodules and liver lesions
- Longitudinal tracking of lesions
- 2D and 3D visualization
- Co-registration
- Automated reporting (Lung-RADS, LI-RADS, RECIST)
- Integration with PACS and EHR
- Real-time collaboration
- Customizable workflows
Use Cases
- Automated detection and quantification of lung nodules in CT scans
- Automated detection and quantification of liver lesions in CT and MRI scans
- Longitudinal tracking of tumors and lesions over time
- Assessing response to cancer treatment
- Standardized reporting for oncology workflows
- Enhancing diagnostic accuracy and efficiency for oncologists and radiologists
What Physicians Need to Know
Arterys Oncology DL is an AI-powered tool designed to enhance efficiency and consistency in the evaluation of lung and liver lesions from CT and MRI scans by automating segmentation and tracking. While it provides accurate, editable results comparable to manual segmentations, the clinician retains ultimate responsibility for the final diagnosis and treatment decisions. Leverage its capabilities for quantitative data, longitudinal tracking, and standardized reporting (Lung-RADS, LI-RADS) to streamline your workflow and improve diagnostic confidence.
The Arterys Oncology DL solution is cloud-based and integrates directly into existing PACS or EHR-driven workflows, making it a natural extension of current practices. It operates on the Arterys MICA platform, ensuring HIPAA compliance and patient data privacy across multiple countries. Integration partners include CrelioHealth LIMS, ARIA Oncology Information System, MOSAIQ Radiation Oncology, CARESTREAM Vue RIS, PacsCube, virtualPACS Gateway, Ambra Health, and MiNNOVAA PACS.
Details
| Category | Oncology AI, Radiology & Imaging AI |
| Pricing | Custom plan — Custom plan; Contact vendor for details |
| Deployment | Cloud-based (SaaS) |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
1 AI-estimated Arterys received FDA 510(k) clearance for its Oncology AI suite (which includes Liver AI and Lung AI) on February 15, 2018, covering all solid tumors. This clearance enables clinicians to measure and track lesions and nodules in MRI and CT scans. |
| Integrations | |
| EHR | Not specified |
| Specialties | Oncology, Radiology |
What the Web Says
Arterys Oncology DL is a cloud-based AI imaging software designed to assist radiologists and oncologists in measuring and tracking tumors and potential cancers. It leverages deep learning to automate the segmentation of lung nodules and liver lesions, aiming to improve diagnostic accuracy and efficiency. The software integrates with existing hospital systems and is accessible via a web browser, complying with patient data privacy and security requirements in numerous countries.
Overall: PositiveStrengths
- Automated segmentation and tracking of lung nodules and liver lesions, with accuracy comparable to manual methods.
- Cloud-based platform (MICA) is easier to deploy than on-premise systems and offers seamless collaboration for second opinions.
- Reduces variability and subjectivity in clinical diagnoses and alleviates radiologist workloads.
- Provides intuitive LI-RADS workflow and score calculation.
- Vendor-agnostic and integrates with PACS, RIS, EMR, and dictation software.
- FDA cleared for clinical use, with multiple FDA approvals for its AI algorithms across various specialties.
Limitations
- Limited public reviews available on platforms like G2 and Capterra, making it difficult to gauge widespread user satisfaction.
- While the technology is advanced, the core information found is from press releases and company statements, which may not reflect independent user experiences.
- No specific negative feedback from physicians or healthcare IT professionals was readily available in the search results.
- The initial deep learning workflows were focused on liver MRI/CT and lung CT scans, with plans for expansion to other solid tumors, implying a phased rollout of capabilities.
- The software is a support tool and does not directly generate diagnoses, requiring interpretation by trained professionals.
Based on reviews from: PR Newswire, Forbes, G2, Applied Radiology, SoftwareWorld, Tempus, Fierce Biotech, DAIC
Last updated: 2026-07-21
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Arterys Oncology DL
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for Arterys Oncology DL.
Arterys Cardio DL (Deep Learning)
Arterys
